Show
Sort by
-
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3) : a phase 3, randomised, double-blind, placebo-controlled study
-
The search for treatments for inclusion body myositis
-
Monkeypox virus infection in humans across 16 countries : April-June 2022
-
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial
-
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study) : a randomised, double-blind, placebo-controlled phase 3 trial
-
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS) : a multicentre, double-blind, phase 3, randomised, placebo-controlled trial
-
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU) : an open-label, single-arm, multicentre, phase 3 trial
-
- Journal Article
- A1
- open access
Potential human transmission of amyloid β pathology : surveillance and risks
-
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT) : a randomised, double-blind, placebo-controlled phase 2b trial
-
The sharp drop in the number of faculty positions is compromising the future of neuroscience